Bio-techne CORP Schedule 13G passive stakes

FMR LLC and Abigail P. Johnson have updated their Schedule 13G filing to reflect beneficial ownership of 8.1% of Bio-Techne Corp's common stock as of June 30, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 5.0% of Bio-Techne Corp's common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 11,559,571 shares, representing 7.38% of Bio-Techne Corp's common stock as of March 31, 2026.

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, reporting a 2.2% beneficial ownership stake in BIO-TECHNE CORP common stock as of September 30, 2025.

T. Rowe Price Associates, Inc. has disclosed an increased beneficial ownership of 5.6% in Bio-Techne Corp.'s common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 7.0% beneficial ownership stake in BIO-TECHNE Corporation's common stock as of June 30, 2025.

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 7.2% beneficial ownership stake in Bio-Techne Corp's common stock as of March 31, 2025.